Clinigen and Accord, a generic pharmaceuticals company, have been partners since 2012 delivering oncology injectable products, including carboplatin, cisplatin and paclitaxel, to clinical trials.
The partnership has grown over the past several years, which a spokesperson for Clinigen said has led to the expansion of the relationship “to bring more products to customers.”
The extended agreement now covers Accord’s European solid dose products, including those in the central nervous system, autoimmune, diabetes, and anti-viral therapy areas.
“The extension of the exclusive agreement will allow Clinigen to have an even larger product offering accessible to our customers ‘on-demand.’ This gives our customers the most flexibility to meet their supply chain needs with the highest quality, and most secure supply chain,” the spokesperson explained.
Products needed for clinical trials will be held in large batch sizes on consignment to be dispatched immediately. Any Clinigen client running clinical trials will have the on-demand supply service available to them. With this, clients will be offered access to products from Accord’s generic oncology injectable product portfolio.
According to Clinigen, this is the first type of service dedicated to providing on demand access to products for clinical trials in the pharmaceutical industry.
Speaking of the partnership advantages a spokesperson for Clinigen told us, “Clinigen was able to partner with a strong manufacturer and provide customers with a dedicated source of many critical products with assurance of quality. Accord was able to tap into Clinigen's global scale and access a broad base of customers with a simplified, supply chain.”